Prevalence of antibiotic resistance in clinical isolates of < em > Mycobacterium kansasii < /em > : a systematic review and meta-analysis

Expert Rev Anti Infect Ther. 2024 Jan 31:1-11. doi: 10.1080/14787210.2024.2313051. Online ahead of print.ABSTRACTINTRODUCTION: The prevalence of diseases caused by non-tuberculous mycobacteria (NTM), including M. kansasii, is increasing, necessitating further information to guide prevention, control, and treatment strategies.AREAS COVERED: A comprehensive analysis of articles published until February 2023 was conducted on PubMed, Web of Science, and Scopus databases to investigate antibiotic resistance in M. kansasii species. Stata software version 17 was employed for all analyses.EXPERT OPINION: A total of 1647 articles were obtained through database search. After removing duplicates and unrelated studies, 17 cross-sectional studies that examined the breakpoints proposed by CLSI were included. The rates of resistance of M. kansasii to various antibiotics were as follows: clarithromycin (0%), rifampin (1%), amikacin (0%), ciprofloxacin (14%), linezolid (0%), moxifloxacin (0%), rifabutin (1%), doxycycline (96%), and SXT (49%). Our findings underscore the importance of managing and monitoring the use of these antibiotics, as well as the need for further studies to elucidate the exact mechanism of M. kansasii resistance to these antibiotics.PMID:38294514 | DOI:10.1080/14787210.2024.2313051
Source: Expert Review of Anti-Infective Therapy - Category: Infectious Diseases Authors: Source Type: research